🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Amneal secures European partner for Parkinson's drug IPX203

EditorEmilio Ghigini
Published 02/27/2024, 09:22 PM
© Reuters.
AMRX
-

BRIDGEWATER, N.J. & CADEMPINO, Switzerland - Amneal Pharmaceuticals, Inc. (NASDAQ: NASDAQ:AMRX) has announced an exclusive licensing agreement with Zambon Biotech SA for the commercialization of IPX203 in the European Union, United Kingdom, and Switzerland.

IPX203 is a novel extended-release oral treatment for Parkinson’s disease, currently under review by the U.S. Food and Drug Administration.

Zambon Biotech, a company with a strong presence in the European neurology market, will seek regulatory approval for IPX203 in these regions. The financial details of the partnership remain undisclosed. This deal aligns with Amneal's strategic aim to ensure global access to its Parkinson's disease treatments.

IPX203 is designed to provide improved control of motor symptoms for patients with Parkinson’s disease compared to immediate-release carbidopa/levodopa. The medication's formulation includes both immediate-release and extended-release components to enhance symptom management.

The licensing agreement is part of Amneal's broader strategy to make IPX203 available worldwide, complementing a previous agreement with Knight Therapeutics Inc. for the drug's commercialization in Canada and Latin America.

Parkinson’s disease is a growing global concern with over 10 million individuals affected, characterized by movement disorders such as tremors and impaired balance. The condition is not fatal but can lead to significant morbidity and disability.

Amneal Pharmaceuticals is a fully integrated global pharmaceutical company, while Zambon Biotech SA is a subsidiary of Zambon, a multinational chemical-pharmaceutical company with a focus on innovative medicines for patient care.

This partnership is expected to leverage Zambon's established neurology footprint in Europe to facilitate the introduction of IPX203 to the market, potentially improving treatment options for Parkinson’s patients across the region.

The information provided is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.